Us benzathine penicillin g market?

Do you want current US market size, brand/generic landscape, or supply/status (shortages)? Here’s a quick snapshot.

- What it is about: Benzathine penicillin G is a long-acting injectable antibiotic used in the US mainly for syphilis (e.g., 2.4 million units total for most cases, given as a single IM dose; regimens vary for late latent disease) and for rheumatic fever prophylaxis.

- US market players:
- Brand: Bicillin L-A (long-acting benzathine penicillin G) and Bicillin C-R (benzathine penicillin G plus procaine penicillin G).
- Generics: Numerous manufacturers supply benzathine penicillin G in the US as generic injectables. The exact list changes as factories come online or go offline.

- Market dynamics:
- This is a relatively small, essential antibiotic market driven by STD rates and prophylaxis guidelines.
- There have been intermittent supply shortages in recent years (notably around 2023–2024), prompting FDA/CDC guidance and temporary imports from other suppliers in some cases.

- Regulatory/clinical notes:
- It is FDA-approved and included in CDC treatment guidelines for syphilis.
- Shortages can affect treatment options, especially for pregnant patients and other settings with limited alternatives.

- Pricing/size data:
- Publicly disclosed, exact US market size figures aren’t routinely published. The market is meaningful for infectious disease treatment but modest compared with chronic meds.

If you tell me what you want specifically (current supply status, brand/generics landscape, or a market size estimate), I can pull in the latest details and any recent FDA shortage updates.